|

Petosemtamab Clinical Trials

3 actively recruiting trials across 2 locations

No change since August 2026

Also known as: GEN1158, MCLA-158

Pipeline

Phase 3: 3

Top Sponsors

  • Genmab2
  • Merus B.V.1

Indications

  • Cancer3
  • Left-sided Colorectal Cancer1
  • Head and Neck Squamous Cell Carcinoma1
  • Colorectal Cancer1

Other1 trial

Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)
Phase 3

Mobile, Alabama1 trial

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

Site 164

Phase 3

Savannah, Georgia1 trial

Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)

Low Country Cancer Care Associates_Savannah_1

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.